Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Oncolytics Biotech ( (ONCY) ).
On September 2, 2025, Oncolytics Biotech released updated clinical safety data for pelareorep, showing a favorable safety profile across over 1,200 patients, including 300 with gastrointestinal tumors. The data supports pelareorep’s potential as a platform therapy, with common adverse events being mild flu-like symptoms. The company is confident that this consistent safety profile will benefit regulatory approval and partnership opportunities, enhancing its position in the immunotherapy market.
The most recent analyst rating on (ONCY) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent. The company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors for metastatic pancreatic and breast cancers, which have received Fast Track designation from the FDA, as well as other gastrointestinal tumors. Oncolytics is actively seeking strategic partnerships to accelerate development and maximize commercial impact.
Average Trading Volume: 1,115,891
Technical Sentiment Signal: Buy
Current Market Cap: $105.3M
For detailed information about ONCY stock, go to TipRanks’ Stock Analysis page.